Stockreport

Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe

Arch Therapeutics, Inc.  (ARTH) 
NASDAQ:AMEX Investor Relations: ir.archtherapeutics.com
PDF FRAMINGHAM, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemosta [Read more]